Dimerix Ltd has released a press release.
Investor Webinar and Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Dimerix
- Dimerix Licenses DMX-200 in the US
- Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
- Trading Halt
- FDA confirms Proteinuria as Primary Endpoint for US approval
- S&P DJI Announces March 2025 Quarterly Rebalance
Later from Dimerix
- Dimerix receives initial upfront payment from Amicus
- Successful planned IDMC review of ACTION3 trial
- 1st ACTION3 site in Japan activated and milestone triggered
- ACTION3 Clinical Trial Milestone Recruitment Update
- Dimerix receives 1st Development Milestone payment from FUSO
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix